United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
Martine A. Rothblatt, United Therapeutics' Chairperson & CEO, reported that a family trust exercised 9,500 stock options at $117.76 per share on October 7, 2026, acquiring 9,500 common shares and selling 9,500 shares in 14 reported sale entries. The exercise and sales were under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The reported stock-option position following the exercise was 280,910 shares.
United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported an exercise of stock options through a family trust for 9,500 common shares on October 6, 2026, at $117.76 per share, followed by sales of 9,500 shares in 17 transactions through family trusts. The sales included 280 shares at a reported weighted-average price of $527.9029 per share and 80 shares at $545.4950 per share. The exercise and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025.
A family trust associated with United Therapeutics Chairperson & CEO Martine A. Rothblatt exercised stock options covering 9,500 common shares on October 5, 2026, at an exercise price of $117.76 per share; family-trust holdings also sold the resulting 9,500 shares. Reported weighted-average sale prices ranged from $536.2579 to $546.6322 per share. The exercise and sales were made under a pre-arranged 10b5-1 trading plan adopted November 7, 2025, set to continue until the earlier of exercise of 1,734,410 stock options, all expiring March 15, 2027, or December 31, 2026.
United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported the exercise of 9,500 stock options held in a family trust at an exercise price of $117.76 per share and the sale by family trusts of 9,500 resulting common shares on October 2, 2026. One reported sale was 700 shares at a weighted-average price of $542.0614 per share. The exercise and sales were pursuant to a pre-arranged Rule 10b5-1 plan adopted November 7, 2025.
The reported stock-option position after the exercise was 309,410. As of October 2, 2026, reported common-stock holdings included 40,513 shares held directly and 166 shares held indirectly by spouse.
United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported exercising 9,500 stock options held by a family trust on October 1, 2026, at an exercise price of $117.76. The trust acquired 9,500 common shares and sold 9,500 shares in 19 reported transactions, with reported weighted-average prices per transaction ranging from $560.05 to $584.6622 per share. The transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The stock-option entry records 318,910 options following the transaction. The footnotes identify the shares as held in family trusts and state that Rothblatt shares investment power over the relevant trust holdings.
United Therapeutics (UTHR) executive vice president and general counsel Paul A. Mahon exercised stock options for 8,300 common shares at a $146.0300 exercise price on October 1, 2026, then sold the resulting 8,300 shares in multiple trades under a pre-arranged 10b5-1 plan. After the exercise, his reported position was 39,240 stock options.
United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported sales of 1,920 common shares on September 30, 2026, through family trusts in which she shares investment power. The eight reported weighted-average prices ranged from $547.2940 to $554.6997 per share. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025.
United Therapeutics Corp. (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust exercised 9,500 stock options with an exercise price of $117.76 per share and acquired 9,500 common shares on September 30, 2026. Family trusts sold 7,580 common shares that day; the exercise and sale of the resulting shares were pursuant to a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. The reported stock-option position after the exercise was 328,410 shares.
United Therapeutics Corp. officer Martine Rothblatt’s notice lists a proposed sale of 209,000 common shares, with an aggregate market value of $113,255,010, through Morgan Stanley Smith Barney LLC. The anticipated sale date is October 1, 2026; the securities entry describes an option exercise from the issuer, with cash listed as payment. Remarks say shares were sold by Rothblatt and/or the Martine Rothblatt Property Management Trust, which she beneficially owns. The notice also lists repeated 9,500-share transactions identified as 10b5-1 sales from July 2 through September 30, 2026.
United Therapeutics officer Paul Mahon reported a proposed sale of 8,300 common shares on October 1, 2026. The notice gives an aggregate market value of $4,689,050.97 and names Morgan Stanley Smith Barney LLC as broker. The shares are listed as acquired from the issuer that day through a stock option exercise, with cash payment. The notice also lists six prior sales from July 2 through September 17, 2026, each for 8,300 shares.